Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Antonio D’Alessio(Hammersmith Hospital), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Maria Isabel Fiel(Icahn School of Medicine at Mount Sinai), Ciro Celsa(Department of Health), Daniel Shu(University of Maryland, Baltimore), Marina Baretti(Sidney Kimmel Comprehensive Cancer Center), Vincent Yip(Barts Health NHS Trust), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Robert Goldin(Imperial College London), Thomas U. Marron(Icahn School of Medicine at Mount Sinai), Yung‐Yeh Su(National Health Research Institutes), Alessio Cortellini(Campus Bio Medico University Hospital), Giulia Francesca Manfredi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Chiun Hsu(National Taiwan University Hospital), Bernardo Stefanini(Azienda USL di Bologna), Mark Yarchoan(Sidney Kimmel Comprehensive Cancer Center), Julia Blanter(Mount Sinai Hospital), Fionnuala Crowley(Icahn School of Medicine at Mount Sinai), Robert Anders(Johns Hopkins University), Stephen C. Ward(Icahn School of Medicine at Mount Sinai), Madhava Pai(Imperial College London), Sarah Slater(Barts Health NHS Trust), Benjamin Adegbite(Mount Sinai Hospital)
Cited by 64
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection
|American Journal of Transplantation|2016|631